The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer

Barbara Melosky,Paul Wheatley-Price,Rosalyn A. Juergens,Adrian Sacher,Natasha B. Leighl,Ming-Sound Tsao,Parneet Cheema,Stephanie Snow,Geoffrey Liu,Paul B. Card,Quincy Chu

Lung Cancer（2021）

引用 40|浏览10

暂无评分

摘要

•Non-small cell lung cancer is heterogenous with many targetable driver mutations.•Tyrosine kinase inhibitors, monoclonal antibodies and conjugates are promising agents.•Targets include ROS1, BRAF, NTRK, MET, uncommon EGFR, RET, HER2, KRAS G12C and NRG1.•FDA approved agents include those targeting ROS1, BRAF V600E, NTRK, MET and RET.•Phase III trials testing ROS1, MET, EGFR, RET, HER2 and KRAS inhibitors are ongoing.

查看译文

关键词

Carcinoma, non-small-cell lung,Molecular targeted therapy,Oncogenes,Oncogene proteins,Oncogene fusion,Point mutation,Gene rearrangement,Gene amplification,Protein kinase inhibitors,Antibody drug conjugate

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要